Valbenazine promotes body growth via growth hormone signaling during zebrafish embryonic development (PRJCA016501)
Valbenazine (VBZ) is a newly FDA-approved oral VMAT-2 inhibitor and used for the treatment of movement disorders such as tardive dyskinesia (TD), and Tourette syndrome (TS). The main purpose of this project is to study the embryonic developmental toxicity of VBZ